Mutations in Alsin are associated with chronic juvenile amyotrophic lateral sclerosis (ALS2), juvenile primary lateral sclerosis and infantile-onset ascending spastic paralysis.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive paralytic disorder caused by degeneration of the upper motor neurons of the motor cortex in brain and lower motor neurons in brainstem and spinal cord, resulting in progressive wasting and paralysis of voluntary muscles 1 . The progressive paralysis in ALS usually affects respiratory function, leading to ventilatory failure and death; 50% of patients die within three years of onset of symptoms and 90% within five years. The juvenile form of ALS usually has a prolonged course extending over two to three decades. There is no known effective treatment for this fatal disease, although marginal delay in mortality has been noted with the drug riluzole 2 .
Most of the ALS cases are sporadic (SALS), but about 5~10% are familial (FALS).
FALS can be transmitted as either a dominant or a recessive trait. Mutations in Cu/Zn superoxide dismutase (SOD1) gene have been shown to be associated with about 20% of FALS cases 3, 4 . Transgenic mice overexpressing ALS-associated mutant SOD1
developed ALS-like phenotype, while transgenic mice overexpressing wild type SOD1 (wtSOD1) remained unaffected 5 , and SOD1 knockout mice did not show motor neuron degeneration 6 , suggesting mutant SOD1 has a toxic property that triggers the motor neuron degeneration in ALS.
We and others have previously shown that mutations in a novel gene, Alsin, cause juvenile ALS type 3 (ALS2), juvenile primary lateral sclerosis (JPLS) or infantile-onset ascending spastic paralysis (IAHSP), depending on the location of the mutations [7] [8] [9] .
Twelve mutations have been reported to date, among which, two (A46fsX50 and T185fsX189) lead to ALS2 and the others seem to result in upper motor neuron syndromes without the involvement of lower motor neurons [7] [8] [9] [10] [11] [12] [13] [14] . Most of these mutations lead to truncated alsin proteins. It is thus postulated that loss of normal function of alsin may trigger the pathogenic process in ALS2. It is well known that in ALS patients with SOD1 mutations and mutant SOD1 transgenic mouse models, a pathological hallmark is the presence of SOD1-containing aggregates or inclusions in neurons 15, 16 . We have recently demonstrated that conversion of SOD1 from soluble form to insoluble aggregates by intermolecular disulfide bonds via redox processes contributes to the pathogenesis of mutant SOD1-mediated ALS (ALS1) 17, 18 . In addition to SOD1, these aggregates also showed immunoreactivity to other cellular proteins 19 . It has been proposed that one of the possible mechanisms leading to motor neuron degeneration in ALS1 is that an essential survival factor for motor neuron is trapped by the SOD1
aggregates, leading to depletion of such a factor and thus triggering the process of the motor neuron degeneration 20 . protected motor neuron cells from the toxicity induced by mutant SOD1 through Rac1/PI3K/Akt3 pathway 21, 22 , raising a possibility that loss of alsin is a shared upstream signal pathway of motor neuron degeneration in both ALS1 and ALS2 or loss of alsin significantly contributes to development of ALS1.
Previous studies of the alsin-deficient mice showed variable phenotypes and pathology [23] [24] [25] [26] . A moderate impairment in motor coordination, a higher level of anxiety response, and increased susceptibility to oxidative stress were observed in one line 23 . A mild loss of Purkinje cells, motor unit remodeling, and gliosis in brain and spinal cord were reported in the second line 24 . Slowness and degeneration of the corticospinal axons in the dorsolateral column were shown in the third line 25 . Motor behavioral abnormalities disturbances in endosome trafficking were observed in the fourth line 26 . The discrepancies in phenotype and pathology in these three alsin-deficient lines were apparent and the reasons for these discrepancies remain unclear.
To address these issues, we developed and characterized a new Alsin knockout mouse model. We show here that ALS2 is predominantly a distal axonopathy, rather than a neuronopathy in the murine central nervous system. This pathology is consistent with the observed predominance of the upper motor neuron symptoms in human subjects with
Alsin mutations, implying important physiological functions of Alsin in maintaining the integrity of the corticospinal axons.
RESULTS

Development of Alsin -/-mice
Human Alsin is relatively a large gene with 83kb genomic DNA in size. It has 34 exons with the first exon being non-coding. Alsin has two transcriptional forms with two distinct poly(A) signals and encodes one short and one long form of protein product, alsin. The short form of Alsin gene has 4 exons and the long form of Alsin has 34 exons.
Both forms share the first 4 exons. We previously reported that a homozygous deletion mutation, A46fsX50 that interrupts both forms of alsin, leads to ALS2. However, a different homozygous deletion mutation, L623fsX647 that only interrupts the long form, leaving the short form intact, leads to JPLS 7 . Mouse Alsin also has two alternatively spliced forms 24 .
To develop a mouse model of ALS2, we constructed a targeting vector designed to replace exon 4 and a part of exon 3 with neo-cassette (Fig.1a) . This vector was designed to target both short and long forms of Alsin, leading to a very short, truncated polypeptide consisting of only 9 amino acids (aa).
Electroporation of the targeting vector into 129S6/SvEv embryonic stem (ES)
cells and subsequent neomycin and gancyclovir selection, yielded 582 ES cell clones. We identified two positive ES cell clones by PCR and Southern blot analysis (Fig.1b, 1c ).
The positive ES cells were used for blastocyst injection. We developed nine highly chimeric male mice, four of which were used for crossbreeding with B6/SJL females to generate heterozygotes. Homozygous Alsin-knockout mice were generated by crossbreeding heterozygous mice (Fig. 1d ). (Fig. 1e) . However, mRNAs with skipping of exon 4 or combined exons 3 and 4 will not be functional, because these skipping are predicted to result in frame shift mutations. As predicted by the targeting vector design, the shared exon 4 genomic DNA sequence by both forms of Alsin was not detected and alsin protein was not produced in Alsin -/-mice ( Fig. 1f and 1g ). The pathology of the ALS2 in humans has never been documented, although clinical presentations in ALS2 patients suggest that the major pathology might be in the upper motor neuron system, including upper motor neurons in the cortex, corticobulbar and corticospinal tracts, with lesser involvement of the low motor neuron system. To uncover pathological changes in the Alsin -/-mice, we analyzed the central nervous system with routine pathological methods such as H&E and thionine Nissl stains. Neither an apparent motor neuron loss nor a gross atrophy was found in motor cortex and spinal cord ( Fig. 2) .
Targeting exons 3 and 4 resulting in skipping of exons 3 and 4 during transcription
Conserved reproductive fitness in
We then applied Amino-Cupric-Silver staining, a very sensitive method for detection of the degenerating or degenerated neuronal cell bodies, dendrites, synaptic terminals, and We previously produced transgenic mice overexpressing ALS1-associated mutants, such as SOD1 G93A (5) and SOD1
L126Z (17) , that developed ALS phenotype and pathology.
Immunohistochemistry shows massive SOD1-containing aggregates which are also ubiquitin-immunoreactive in neurons and their neuritic processes in the spinal cord sections (Fig. 5a-c) . To examine if alsin is trapped in these aggregates, we stained the spinal cord sections of the affected mice using anti-alsin antibodies. We found that alsin is highly expressed in large neurons in cortex, brain stem, and spinal cord. It is mainly distributed in cytoplasm and neuronal processes. However, we did not find apparent aggregates that are positive either alone or together with ubiquitin ( Fig. 5d-f ), suggesting that alsin is not a major component in SOD1/ubiquitin-immunoreactive aggregates.
Loss of alsin does not change the disease course of ALS1 in SOD1 G93A mice
Degeneration of the motor neuron system is a shared pathology in both ALS1 and ALS2.
The upstream signaling pathways triggering the degeneration in ALS1 and ALS2 are unknown. ALS1 is a dominant disease caused by mutations in SOD1 through a gain of function mechanism. ALS2 is a recessive disease that is likely linked to loss of alsin. It was reported that alsin protected motor neurons from the toxicity induced by mutant SOD1 through RAC/PI3K/Akt3 pathway 21 Fig. 5g and h ).
DISCUSSION
Our Alsin -/-mice showed motor deficits, confirming alsin's function in motor activity in mammals. Motor deficit on Rotarod test was observed in two of the previously reported three Alsin -/-mouse lines 23, 25 , but not in another line 24 . We observed that the Rotarod performance could vary substantially from day to day when the mice were not well trained. The performance could be improved and become relative stable after a 10 minutes training every day for 3-4 weeks. We also observed that the well-trained Alsin -/-mice remained on the Rotarod at a speed of 20 rpm for over 300 seconds, as the control mice did. The difference became apparent when the Rotarod speed was increased to 40rpm for 400 seconds, indicating that the motor deficit in the Alsin -/-mice was mild.
The pathology of ALS2 in humans has not been elucidated. 24 . But such a loss was not detected in another line 25 . We used the AminoCupric-Silver staining which can detect degeneration of the surviving cells and their neuritic processes 28, 29 . We detected non-disease-specific neuronal cell degeneration in both control and alsin-deficient mice, but we did not found degeneration of Purkinje cells in our Alsin -/-mice, suggesting that the degeneration of Purkinje cells may not be a common feature in alsin-deficient mouse models. Recently, an increased susceptibility to glutamate receptor-mediated excitotoxicity was observed in the cultured spinal cord slice of alsin-deficient mice 30 . Since we did not find apparent increase in motor neuron degeneration in our alsin-deficient mice compared with controls, it remains to be further addressed if this increased susceptibility has significant contribution to the pathogenesis of ALS2 in in vivo system. Progressive degeneration of spinal cord axons was reported predominantly in the dorsolateral column, rather than dorsal column in the third alsindeficient mouse line using conventional toluidine blue staining 25 . We also observed the degeneration of dorsolateral CST axons, but the degeneration in the dorsal CST seemed more apparent using Amino-Cupric-Silver staining in our mouse model. These discrepancies in phenotype and pathology among different alsin-deficient mouse models may be attributed in part to the differences in mouse genetic backgrounds, regions of alsin to be targeted and approaches for evaluation.
The physiological function of alsin remains unknown. 34 , suggesting that loss of alsin is neither responsible for, nor significantly contributes to, the development of ALS1. Thus, loss of alsin is not the signaling pathway triggering motor neuron degeneration in ALS1. Therefore, it seems likely that the signaling pathways triggering motor neuron degeneration in ALS1 and ALS2 are independent. Importantly, unlike in humans, the input from the CST seems not essential for normal overground locomotion in rodents 37 , possibly due to lack of direct cortico-motoneuronal synaptic connections between corticospinal axon boutons and motor neurons in anterior horns 38 . In addition to mice, other mammals and primates such as cats and monkeys are also able to locomote overground after transection of the CST with only a brief recovery period [39] [40] [41] . The overall body and limb movements are almost indistinguishable from those of the unlesioned animals, but the dedicated independent movements of the individual fingers were incapacitated in the lesioned animals 41 . This notion is also Confocal microscopy. The basic procedures for confocal microscopy were previously described 17 .
Amino cupric silver staining. Mice were anesthetized with sodium pentobarbital (150mg/kg) and perfused through the heart with a rinsing solution of 0.8% sodium chloride, 0.4% dextrose, 0.8% sucrose, 0.023% calcium chloride and 0.034% sodium cacodylate followed by a perfusion fixative of 4% paraformaldehyde, 4% sucrose and A serial set of every sixth section (a 240um interval) was selected for staining with the amino-cupric-silver stain of de Olmos to reveal disintegrative degeneration 28 and
Thionine Nissl staining.
The free-floating sections were taken through the following major steps:
preimpregnation, impregnation, reduction, bleaching, and fixing. The sections were then rinsed in deionized water, mounted on subbed glass slides, and counterstained with neutral red to reveal normal cell bodies.
Rotarod test.
Beginning at age 360 days, alsin knockout homozygotes and controls were n=8) compared to the control SOD1 G93A mice (blue line, onset: 103.7 ± 11.7 days, n=27;
lifespan: 128.6 ± 9.4, n=24; P=0.508 and P=0.633, respectively).
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